Technical Analysis for VCYT - Veracyte, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 20.75 | -1.14% | -0.24 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 50 DMA | Bearish | 0.00% | |
| Stochastic Reached Oversold | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| Crossed Above 50 DMA | Bullish | -1.14% | |
| Gapped Up | Strength | -1.14% | |
| Fell Below 20 DMA | Bearish | -0.19% | |
| Fell Below 50 DMA | Bearish | -0.19% | |
| Inside Day | Range Contraction | -0.19% | |
| Gapped Down | Weakness | -0.19% | |
| Crossed Above 20 DMA | Bullish | -3.26% |
| Alert | Time |
|---|---|
| Fell Below Previous Day's Low | 1 day ago |
| Possible Inside Day | 1 day ago |
| Fell Below 50 DMA | 1 day ago |
| 50 DMA Support | 1 day ago |
| Down 1% | 1 day ago |
Get a Trading Sidekick!
- Earnings date: 05/02/2024
Veracyte, Inc. Description
Veracyte, Inc. operates as a diagnostics company in the field of molecular cytology to enhance patient outcomes and lower healthcare costs. It provides Afirma Thyroid FNA Analysis, a solution that consists of its Gene Expression Classifier (GEC), which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. The company is also developing Afirma Malignant GEC test for rare forms of thyroid cancer or metastases to the thyroid that is intended to inform surgical strategy; and idiopathic pulmonary fibrosis and nodules suspicious products for lung cancer. It serves endocrinologists, radiologists, and head and neck specialists. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Telehealth Telemedicine Gene Expression Lung Cancer Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Thyroid Healthcare Costs Metastases Glands Surgeries Thyroid Cancer
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 30.52 |
| 52 Week Low | 18.61 |
| Average Volume | 679,085 |
| 200-Day Moving Average | 23.56 |
| 50-Day Moving Average | 20.82 |
| 20-Day Moving Average | 21.55 |
| 10-Day Moving Average | 21.42 |
| Average True Range | 0.86 |
| RSI (14) | 45.65 |
| ADX | 15.79 |
| +DI | 23.85 |
| -DI | 21.54 |
| Chandelier Exit (Long, 3 ATRs) | 21.31 |
| Chandelier Exit (Short, 3 ATRs) | 22.06 |
| Upper Bollinger Bands | 23.58 |
| Lower Bollinger Band | 19.53 |
| Percent B (%b) | 0.3 |
| BandWidth | 18.79 |
| MACD Line | 0.05 |
| MACD Signal Line | 0.22 |
| MACD Histogram | -0.1738 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.82 | ||||
| Resistance 3 (R3) | 21.91 | 21.66 | 21.64 | ||
| Resistance 2 (R2) | 21.66 | 21.39 | 21.61 | 21.58 | |
| Resistance 1 (R1) | 21.20 | 21.22 | 21.08 | 21.11 | 21.52 |
| Pivot Point | 20.95 | 20.95 | 20.88 | 20.90 | 20.95 |
| Support 1 (S1) | 20.49 | 20.68 | 20.37 | 20.40 | 19.98 |
| Support 2 (S2) | 20.24 | 20.51 | 20.19 | 19.92 | |
| Support 3 (S3) | 19.78 | 20.24 | 19.86 | ||
| Support 4 (S4) | 19.69 |
